MS therapeutics: 1 withdrawal, 1 setback

 

Daclizumab (Zinbryta), the anti-CD25 monoclonal antibody approved for the treatment of relapsing MS in May 2016 (December 2016 in Canada), has been voluntarily withdrawn by its manufacturers and will no longer be available. The withdrawal was announced on March 2, in a press release issued by Biogen and AbbVie (www.businesswire.com/news/home/20180302005168/en/Biogen%C2%A0and-AbbVie-Announce%C2%A0the-Voluntary%C2%A0Worldwide-Withdrawal-Marketing-Authorizations).

The drug was withdrawn following eight reports of inflammatory encephalitis and meningoencephalitis in Germany and Spain. As a result of these cases, the European Medicines Agency had announced that it was urgently reviewing Zinbryta under its Article 20 pharmacovigilance procedure.

It takes 30 seconds

TOPICS:
Recommend to a Colleague

Related Posts

Go back to home page